Shares of Prelude Therapeutics rose after the company said it has received Food and Drug Administration approval to proceed with a Phase 1 study for blood-cancer treatment. Shares were up 9.4% at ...
In 2026, the spotlight will be on a handful of therapeutic strategies that could change cancer care for patients by offering ...
DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified pyrrolobenzodiazepine payload.
Eli Lilly (NYSE:LLY) announced a collaboration with Repertoire Immune Medicines to develop next generation autoimmune ...
The field of cancer research has increasingly focused on the metabolic underpinnings of tumorigenesis, recognizing how the reprogramming of cellular energy ...
Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a ...
Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...
Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...
A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a first-in-class chemical inhibitor that precisely and selectively targets the ATAC ...
ImmunityBio Chairman Patrick Soon-Shiong mischaracterized talks with the FDA over the company's cancer drug, sources say.
Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results